Cronos Group Inc. to Hold 2024 Second Quarter Earnings Conference Call on August 8, 2024
TORONTO, July 25, 2024 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold…
Pharmaceuticals, Biotechnology and Life Sciences
TORONTO, July 25, 2024 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold…
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic…
MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) — TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on…
BASEL, Switzerland and LONDON and NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today announced that it…
LEXINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that…
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical…
– Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody® ADG126 (muzastotug) with higher, more frequent and repeat dosing in combination…
Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis.1This patent strengthens…
BOSTON, July 24, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology…
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical…